Axogen Q4: EPS Miss Amid Biologics Transition

分组1 - Axogen, Inc. (AXGN) reported a 4Q25 non-GAAP EPS of $0.07, missing expectations by approximately $0.03 [1] - Revenue for the quarter was $59.9 million, aligning with estimates and reflecting a year-over-year growth of 21.3% [1]